According to a meta-analysis based on nine studies, conducted by Van Sanden et al. in 2022, the frequency of exon 20 insertion alterations ranged 2.5–23.1% within EGFR positive patients with NSCLC and 0.3–2.2% amongst a general NSCLC population [5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.